Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Ciraparantag Safely and Effectively Reverses Apixaban and Rivaroxaban in Age-Matched Healthy Volunteers As Measured By Whole Blood Clotting Time

Bryan Laulicht, PhD, Sasha Bakhru, PhD, Solomon Steiner, PhD, Jack Ansell, MD

Blood (2018) 132 (Supplement 1): 987.

https://doi.org/10.1182/blood-2018-99-116754

Published: 2018

Journal Articles

Results of the First American Prospective Study of IV Iron in Oral Iron Intolerant Iron Deficient Gravidas

Michael Auerbach, MD, Samuel Smith, MD, Stephanie James, MD

Blood (2016) 128 (22): 1277.

https://doi.org/10.1182/blood.V128.22.1277.1277

Published: 2016

Journal Articles

A Retrospective Comparison of Adverse Reaction Rates with the Use of Three Intravenous Iron Formulations: A Single Center Experience.

Maureen Okam, MD, Elyse Mandell, ANP

Blood (2010) 116 (21): 1537.

https://doi.org/10.1182/blood.V116.21.1537.1537

Published: 2010

Journal Articles

Clinical Efficacy and Safety Versus Biological Response of Desmopressin (DDAVP) In Inherited Von Willebrand Disease (VWD) Types 1 and 2: Initial Results From the International Study Group on DDAVP In VWD In a Cohort of 229 Patients

Augusto B. Federici, MD, Alfonso Iorio, MD, Giancarlo Castaman, MD

Blood (2010) 116 (21): 238.

https://doi.org/10.1182/blood.V116.21.238.238

Published: 2010

Journal Articles

Modeling Chronic Graft-Versus-Host-Disease: A New MHC-Matched Model of Late-Onset Scleroderma After Low-Dose Conditioning and Hematopoietic Cell Transplantation That Affects Only Male Recipients of Female Grafts.

Antonia MS Mueller, David Miklos, MD, PhD, Judith Shizuru, PhD, MD

Blood (2009) 114 (22): 3560.

https://doi.org/10.1182/blood.V114.22.3560.3560

Published: 2009

Journal Articles

Manageable Side Effects of Intravenous Iron in a Community Practice

Nicole Brown, BA, David H. Henry, MD, Patricia A. Ford, MD

Blood (2008) 112 (11): 4687.

https://doi.org/10.1182/blood.V112.11.4687.4687

Published: 2008

Journal Articles

Burkitt Transformation of Mantle Cell Lymphoma.

Kavita S. Reddy, PhD, Mohammad Ansari-Lari, MD, Bruce Dipasquale, MD

Blood (2007) 110 (11): 4129.

https://doi.org/10.1182/blood.V110.11.4129.4129

Published: 2007

Journal Articles

Heme/Fe-S intimacies make RBCs blush

Carole Beaumont

Blood (2007) 110 (4): 1085–1086.

https://doi.org/10.1182/blood-2007-05-091405

Published: 2007

Journal Articles

High Dose Intranasal Desmopressin (DDAVP) Therapy in Type 2M Von Willebrand Disease (VWD): A Prospective Open Label Trial.

Rekha Parameswaran, MD, Jorge Di Paola, MD, Lorrie Miller-Rice, MD, Anne Greist, MD, Amy D. Shapiro, MD

Blood (2005) 106 (11): 1783.

https://doi.org/10.1182/blood.V106.11.1783.1783

Published: 2005

Journal Articles

Successful treatment of severe bleeding in hemophilic target joints by selective angiographic embolization

Eveline P. Mauser-Bunschoten, Jacco A. C. Zijl, Willem Mali, A. Cees van Rinsum, H. Marijke van den Berg, Goris Roosendaal

Blood (2005) 105 (7): 2654–2657.

https://doi.org/10.1182/blood-2004-06-2063

Published: 2005

Journal Articles

Clofarabine Plus Cytarabine (ARA-C) Combination Is Active in Newly Diagnosed Patients (PTS) ≥ Age 50 with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).

Stefan Faderl, MD, Varsha Gandhi, PhD, Srdan Verstovsek, MD, PhD, Jorge Cortes, MD, Farhad Ravandi-Kashani, MD, Miloslav Beran, MD, PhD, Guillermo Garcia-Manero, MD, Charles Koller, MD, Susan O’Brien, MD, Alessandra Ferrajoli, MD, Zeev Estrov, MD, Monica Kwari, RN, William Plunkett, PhD, Hagop M. Kantarjian, MD

Blood (2004) 104 (11): 875.

https://doi.org/10.1182/blood.V104.11.875.875

Published: 2004

Journal Articles

AGF will make you blush

Francesco Bertolini

Blood (2004) 103 (10): 3610–3611.

https://doi.org/10.1182/blood-2004-02-0632

Published: 2004

NARROW

Ciraparantag Safely and Effectively Reverses Apixaban and Rivaroxaban in Age-Matched Healthy Volunteers As Measured By Whole Blood Clotting Time

Results of the First American Prospective Study of IV Iron in Oral Iron Intolerant Iron Deficient Gravidas

A Retrospective Comparison of Adverse Reaction Rates with the Use of Three Intravenous Iron Formulations: A Single Center Experience.

Clinical Efficacy and Safety Versus Biological Response of Desmopressin (DDAVP) In Inherited Von Willebrand Disease (VWD) Types 1 and 2: Initial Results From the International Study Group on DDAVP In VWD In a Cohort of 229 Patients

Modeling Chronic Graft-Versus-Host-Disease: A New MHC-Matched Model of Late-Onset Scleroderma After Low-Dose Conditioning and Hematopoietic Cell Transplantation That Affects Only Male Recipients of Female Grafts.

Manageable Side Effects of Intravenous Iron in a Community Practice

Burkitt Transformation of Mantle Cell Lymphoma.

Heme/Fe-S intimacies make RBCs blush

High Dose Intranasal Desmopressin (DDAVP) Therapy in Type 2M Von Willebrand Disease (VWD): A Prospective Open Label Trial.

Successful treatment of severe bleeding in hemophilic target joints by selective angiographic embolization

Clofarabine Plus Cytarabine (ARA-C) Combination Is Active in Newly Diagnosed Patients (PTS) ≥ Age 50 with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).

AGF will make you blush

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only